Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlo Fabris

Showing results (1-10 of 68) with videos related to

Pageof 7
Sort By:
Expert Opinion on Pharmacotherapy|October 6, 2006
Antiviral treatment of hepatitis CPierluigi Toniutto, Carlo Fabris, Mario Pirisi
Hepatology (Baltimore, Md.)|April 5, 2013
Reply: To PMID 22610885Edmondo Falleti, Carlo Fabris, Pierluigi Toniutto
Liver International : Official Journal of the International Association for the Study of the Liver|March 11, 2010
Sarcoidosis or foreign-body granulomatous reaction during interferon treatment?Davide Bitetto, Elisa Fumolo, Carlo Fabris, et al.
Journal of Hepatology|February 26, 2011
Vitamin D deficiency and HCV chronic infection: what comes first?Davide Bitetto, Carlo Fabris, Edmondo Falleti, et al.
Expert Opinion on Medical Diagnostics|March 15, 2013
Combinatorial use of single nucleotide polymorphisms to help predict liver fibrosis in patients with hepatitis C infectionsRosalba Minisini, Carlo Fabris, Pierluigi Toniutto, et al.
Discovery Medicine|March 9, 2007
Updates on antiviral therapy for chronic hepatitis CPierluigi Toniutto, Carlo Fabris, Davide Bitetto, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 24, 2015
PNPLA3 rs738409 and TM6SF2 rs58542926 variants increase the risk of hepatocellular carcinoma in alcoholic cirrhosisEdmondo Falleti, Annarosa Cussigh, Sara Cmet, et al.
Annals of Hepatology|February 5, 2016
Usefulness of acoustic radiation force impulse and fibrotest in liver fibrosis assessment after liver transplantSara Bignulin, Edmondo Falleti, Sara Cmet, et al.
Journal of Clinical Medicine|May 14, 2025
Modifiable and Non-Modifiable Risk Factors and Vascular Damage Progression in Type 2 Diabetes: A Primary Care AnalysisCarlo Fabris, Elena Rizzo, Stefano Bertolissi, et al.
Idrugs : the Investigational Drugs Journal|October 2, 2008
R-1626, a specific oral NS5B polymerase inhibitor of hepatitis C virusPierluigi Toniutto, Carlo Fabris, Davide Bitetto, et al.
Pageof 7

Showing results (1-10 of 68) with videos related to

Sort By:
Pageof 7
Expert Opinion on Pharmacotherapy|October 6, 2006
Antiviral treatment of hepatitis CPierluigi Toniutto, Carlo Fabris, Mario Pirisi
Hepatology (Baltimore, Md.)|April 5, 2013
Reply: To PMID 22610885Edmondo Falleti, Carlo Fabris, Pierluigi Toniutto
Liver International : Official Journal of the International Association for the Study of the Liver|March 11, 2010
Sarcoidosis or foreign-body granulomatous reaction during interferon treatment?Davide Bitetto, Elisa Fumolo, Carlo Fabris, et al.
Journal of Hepatology|February 26, 2011
Vitamin D deficiency and HCV chronic infection: what comes first?Davide Bitetto, Carlo Fabris, Edmondo Falleti, et al.
Expert Opinion on Medical Diagnostics|March 15, 2013
Combinatorial use of single nucleotide polymorphisms to help predict liver fibrosis in patients with hepatitis C infectionsRosalba Minisini, Carlo Fabris, Pierluigi Toniutto, et al.
Discovery Medicine|March 9, 2007
Updates on antiviral therapy for chronic hepatitis CPierluigi Toniutto, Carlo Fabris, Davide Bitetto, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 24, 2015
PNPLA3 rs738409 and TM6SF2 rs58542926 variants increase the risk of hepatocellular carcinoma in alcoholic cirrhosisEdmondo Falleti, Annarosa Cussigh, Sara Cmet, et al.
Annals of Hepatology|February 5, 2016
Usefulness of acoustic radiation force impulse and fibrotest in liver fibrosis assessment after liver transplantSara Bignulin, Edmondo Falleti, Sara Cmet, et al.
Journal of Clinical Medicine|May 14, 2025
Modifiable and Non-Modifiable Risk Factors and Vascular Damage Progression in Type 2 Diabetes: A Primary Care AnalysisCarlo Fabris, Elena Rizzo, Stefano Bertolissi, et al.
Idrugs : the Investigational Drugs Journal|October 2, 2008
R-1626, a specific oral NS5B polymerase inhibitor of hepatitis C virusPierluigi Toniutto, Carlo Fabris, Davide Bitetto, et al.
Pageof 7